Sermorelin vs CJC-1295: A Research Compound Comparison

You’ll almost never catch anyone discussing sermorelin without CJC-1295 getting dragged into the same sentence, and once you know they’re built on the identical backbone (GRF(1-29), the active N-terminal piece of growth hormone releasing hormone) that habit starts to make sense, because the only thing that genuinely separates the two is how long each one manages to hang around in plasma, a difference that traces back to a single chemical tweak and yet somehow drives nearly every argument people get into about the pair. We’ll keep this to what the primary literature actually measured, with the sources linked so you can push back.

If you want the shape of it up front: both are GHRH analogs on the GRF(1-29) backbone hitting the same GHRH receptor [1], sermorelin clears within minutes because DPP-IV chops its N-terminus and that’s the end of it [2], whereas CJC-1295 carries a maleimidopropionamide group that bonds to serum albumin at Cys34, and that one addition was enough to keep it detectable in rat plasma past 72 hours [3]. In people, the same molecule drove plasma growth hormone up somewhere between 2 and 10 fold for 6 days or more, with a half-life that landed between 5.8 and 8.1 days [4].

Same backbone, same receptor

Both molecules are versions of GRF(1-29), which is the shortest fragment of GHRH that still carries the full activity of its 44 residue parent [1], and they bind the same target, the GHRH receptor on somatotroph cells in the anterior pituitary, a class B G protein coupled receptor that signals through adenylyl cyclase and cyclic AMP [5]. So at the receptor itself there’s really nothing to choose between sermorelin and CJC-1295, they’re doing the same job in the same place.

The one difference that matters: time

Stability is where they split. Sermorelin, as plain GRF(1-29), has a His-Ala N-terminus that dipeptidyl peptidase IV clips fast, killing the peptide within minutes [2]. That’s a hard ceiling on its duration, and no protocol changes how fragile the molecule is.

CJC-1295 was engineered to dodge exactly that. Jetté and colleagues attached a maleimido group to hGRF(1-29) so it would react with the free thiol on Cys34 of serum albumin [3]. Albumin circulates for weeks, so the bound peptide tags along for the ride. Their best conjugate, named CJC-1295, shrugged off DPP-IV, produced a 4 fold bigger growth hormone area under the curve over 2 hours than unmodified hGRF(1-29), and showed up on the albumin band of a Western blot past 24 hours.

What the human data showed for CJC-1295

When Teichman and colleagues ran CJC-1295 through two placebo-controlled trials in healthy adults aged 21 to 61, mean plasma growth hormone climbed somewhere between 2 and 10 fold for 6 days or longer while IGF-I rose 1.5 to 3 fold and held for 9 to 11 days, the half-life worked out to between 5.8 and 8.1 days, and with repeated exposure IGF-I was still above baseline as far out as 28 days [4]. Sermorelin reads nothing like that in the literature, where it shows up instead as a quick, short-lived diagnostic stimulus, an intravenous 1 microgram per kilogram amount drawing a rapid and fairly specific growth hormone response and then fading [1].

Side by side

Why researchers pick one over the other

It really does come back to the time course you’re after, because a short sharp pulse of pituitary activity is where sermorelin fits (its fast clearance keeps the signal clean and brief) while a sustained lift spread over several days is CJC-1295 territory, and the albumin anchor is the only reason it has that shape at all, so neither one wins so much as they answer different experimental questions. Worth noting while we’re here that the “without DAC” form of CJC-1295 behaves a lot like sermorelin anyway, since it never carried the albumin group to begin with. For the full DAC breakdown, see our CJC-1295 DAC overview, and for the receptor families underneath these peptides, our GHRH versus GHRP overview.

Two questions people keep asking

Are they the same peptide? Not quite, though the confusion is fair. They share the GRF(1-29) backbone and the same receptor, so at the business end they’re twins. The difference is one albumin-binding group that CJC-1295 carries and sermorelin doesn’t [3]. And why does CJC-1295 last so much longer? Same answer, really. That maleimido group bonds to serum albumin, albumin circulates for weeks, and so the peptide’s time in plasma stretches from minutes out to days [4]. One edit, a completely different time course.

References

1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PMID 18031173
2. Bai JP, Chang LL. The involvement of dipeptidyl peptidase IV in brush-border degradation of GRF(1-29)NH2 by intestinal mucosal cells. J Pharm Pharmacol. 1995. PMID 8583376
3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669
4. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683
5. Cunha SR, Mayo KE. Ghrelin and growth hormone secretagogues potentiate GHRH-induced cyclic AMP production in cells expressing cloned GHRH and GHS receptors. Endocrinology. 2002. PMID 12446584